May 7 |
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
|
Apr 30 |
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
|
Apr 30 |
Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition
|
Apr 26 |
Repare Therapeutics appoints Steven Stein to its board of directors
|
Apr 26 |
Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors
|
Apr 20 |
Repare Therapeutics Inc.'s (NASDAQ:RPTX) market cap dropped US$21m last week; Private equity firms bore the brunt
|
Mar 1 |
Repare Therapeutics Full Year 2023 Earnings: Misses Expectations
|
Feb 28 |
Repare Therapeutics GAAP EPS of -$0.67 misses by $0.34, revenue of $13.05M misses by $5.88M
|
Feb 28 |
Repare Therapeutics Inc (RPTX) Reports Financial Outcomes for Q4 and Full Year 2023
|
Feb 28 |
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
|